Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX, pending details of a capital raising,
During FY16, the healthcare company grew its sales to $14.1 million, up 40% on FY15 sales.
Furthermore, the company is forecasting over 50% revenue growth in the current financial year through growing the infusion sales business, CardioCel sales growth and introducing additional products.
The halt will remain in place until the opening of trade on Friday 29th July 2016, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.
